Embed Size (px)
Citation preview
Juan Jenny Li works as a chemistry professional at Novo Nordisk’s research centre in Beijing
Diabetes
Haemophilia
Protein Technologies
Protein Delivery Devices
novo nordiskPartnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES
Novo Nordisk is a world leader in diabetes care and we have a leading position within haemostasis management, growth hormone therapy, and hormone replacement therapy. We have refined our protein competencies since 1923, and have developed world class expertise in driving proteins from molecule to market.
Novo Nordisk is a focused healthcare company
We leverage our protein knowledge to discover and develop new protein therapeutics and formulations.
We master all aspects of protein and peptide drug development. We are pioneers in developing patient-friendly delivery systems.
Novo Nordisk way of partnering
Our history tells us that creativity thrives in partnerships. We are dedicated to patient care and to our business, and we are open to a wide range of partnering models from in-licensing to sophisticated partnerships. Novo Nordisk works with a carefully defined process from opportunity identification to deal making to ensure optimal communication with our potential partners.
Corporate Alliance Management ensures fruitful collaboration during the alliance
Identifi-cation
Initial Evaluation
In-depth Evaluation
Due Diligence
Deal Making Alliance
? !OpportunityIdentification Assessment Partnering
Our Sourcing Units identify partnering opportunities and initiate and coordinate evaluations
Business Development drives the due diligence process, negotiates the deal and ensures efficient collaboration and communication through the deal-making process
Exp
ression Delivery sy
stem
s
Formulation
Ratio
nal D
esign
Clinical, Medical, Regulatory
AcylationModification
Amino acid substitution
Liquid formulationsCombination products
Oral protein delivery
Prefilled pensDurable pens
E.coliYeast
Mammalian cells
Therapy area expertiseMedical insightTrial design
Execution and report
The Triple Bottom Line is the principle that guides Novo Nordisk’s way of doing business. It primes our business for long-term growth and drives our commitment to sustainable development: to meet the needs of the present without compromising the ability of future generations to meet their needs.
In day-to-day business, this implies that all decisions must seek to balance three considerations: Is it economically viable? Is it socially responsible? Is it environmentally sound? This is the Triple Bottom Line, which ensures that decision-making balances financial growth with corporate responsibility, short-term gains with long-term growth, and shareholder return with other stakeholder interests.
Novo Nordisk way of doing business
Economically viable
Sociallyresponsible
Environmentallysound
With headquarters in Denmark, Novo Nordisk has approximately 40,700 employees in 75 countries, and we market our products in more than 180 countries. Approximately 42% of employees are located in Denmark and 58% in the rest of the world. 18% are within research and development.
Our main research site is in Copenhagen, Denmark. Novo Nordisk’s research centre in Beijing was the first research centre established in China by an international pharmaceutical company. It is evolving into a centre of excellence in molecular biology, protein chemistry and cell biology. Novo Nordisk’s research centre in Seattle, USA, is a centre of excellence in translational research in type 1 diabetes, immunology and cytokine biology.
Learn more at www.novonordisk.com/science/partnering
Partnering 2014 / www.novonordisk.com/science/partnering
Contacts
Diabetes & Protein Technologies
Finn Benned Hansen Corporate Vice President, e-mail: [email protected]
Haemophilia & Growth Hormone
Jørn Roland Müller Director, e-mail: [email protected]
Protein Delivery Devices
Morten Bæk Jensen Innovation Sourcing Director, e-mail: [email protected]
Novo Nordisk research on the map
Copenhagen, DenmarkSeattle, WA, USA Beijing, China
Diabetes & Protein Technologies
Novo Nordisk has been a world leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition. We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention. We master all aspects of protein and peptide drug development and target our efforts on improving blood sugar control, which is essential for preventing and delaying diabetes-related complications. Novo Nordisk R&D focuses on new insulin and GLP-1 analogues, other new treatments for diabetes, including its microvascular complications, obesity, and on protein technologies and delivery systems. Our research and development into the oral delivery of protein and peptide therapeutics promises to bring people with diabetes new treatment options for the safe and effective management of their disease.
We develop and market pharmaceutical products and services that make a significant difference to patients, the medical profession and society. We have a proven track record and the capabilities to succeed.
Novo Nordisk is actively searching for partnerships and collaborations. We invite you to become part of our success.
Innovation Sourcing in DiabetesChuck Gray Sourcing Director, e-mail: [email protected]
Barbara AraneoSourcing Director, e-mail: [email protected]
Finn Benned Hansen Corporate Vice President, e-mail: [email protected] Martin E. Judge Sourcing Director, e-mail: [email protected] Tomas Landh Sourcing Director, e-mail: [email protected]
Diabetes Partnering 2014 / www.novonordisk.com/science/partnering
Protein and peptide technologies:• Expression• Modification• Production
Formulation and drug delivery technologies for proteins and peptides:• Liquid• Oral• Sustained/triggered release
Technologies
Our partneringfocus
Compounds
Insulin and GLP-1 receptor peptide-agonists: • Insulins and GLP-1s with novel therapeutic properties
• Optimised for oral delivery
• Modified duration of action
• Improved side-effect profile
Therapeutic proteins and peptides affecting:
• Glucose regulation with additional benefits• Insulin secretion• Insulin resistance• Beta-cell mass• Obesity• Diabetes late-stage complications • Inflammation related to diabetes and obesity• Prevention/progression of diabetes
Technologies enabling immunogenicity prediction and tolerance induction:
Technologies for monoclonal antibodies:• Generation, selection and functional screening of mAbs• Novel antibody formats including bispecific mAbs and antibody drug conjugates• Activity enhanced mAbs including optimisation of half-life and Fc-receptor interaction
Our partneringfocus
Our aspiration is to change possibilities for treating people with haemophilia. Every step of our journey is focused on improving treatment options and access to care, by using our commitment to innovate, understand disease mechanisms and patient needs.
We are constantly seeking collaborators and partners who share this ambition.
Our research and development in haemophilia began over 20 years ago, to address the unmet treatment need of people with haemophilia and inhibitors, ie neutralizing antibodies to replacement therapy.
Novo Nordisk’s commitment to haemophilia is, however, not limited to this single innovation. We continue to expand our haemophilia pipeline and we are actively seeking partnerships and collaborations across the haemophilia care segment and invite you to become part of our success.
The Novo Nordisk approach to changing possibilities in haemophilia includes:
• Improving replacement therapies for haemophilia A and B without inhibitors • Improving bypassing therapies for inhibitor-complicated haemophilia A and B • Understanding disease mechanisms and identifying biomarkers relevant to diagnosing and treating haemophilia
Haemophilia
Haemophilia Partnering 2014 / www.novonordisk.com/science/partnering
Haemostasis Sourcing
Jørn Roland Müller Director, e-mail: [email protected]
Anand Gautam Sourcing Director, e-mail: [email protected]
We seek partners and opportunities within treatment, prevention and detection of bleeding in people with haemophilia:
• Improvement of FVIII and FIX based replacement therapies for people with haemophilia A or B, including protraction technologies for long-acting prophylaxis and less immunogenic products
• Improvement of bypassing therapies for on-demand as well as prophylactic therapy in people with haemophilia
• Detection, prevention and treatment of haemophilic arthropathy• Improved technologies, for eg expression, formulation and delivery of biopharmaceuticals for
haemophilia• Identification of novel treatment concepts including non-replacement therapies that improve
haemostasis in people with haemophilia
Novo Nordisk designs protein delivery devices that meet the everyday needs of people with chronic diseases like diabetes, haemophilia and growth hormone deficiencies.
In 1985, Novo Nordisk introduced the world’s first insulin pen device designed for multiple daily injections. Since then, we have made extensive efforts in research and development of new delivery systems which will help people with chronic diseases manage protein therapy.
Today, we are market leaders of insulin devices and growth hormone delivery systems.
With more than 300 engineers, technicians and scientists, we have established a device R&D organisation focusing on improving the lives of the millions of people who need protein delivery.
We want to continue to set the global standard for application and integration of new materials, technologies and concepts into ground-breaking device solutions for protein delivery.
Innovation is our obligation. We develop high precision products for large-scale production. We work in project teams which involve advanced mechanical and electronic engineering as well as a growing number of external partners.
We are actively searching for partnerships and collaborations to develop better delivery systems for people with chronic diseases.
Device Partnering 2014 / www.novonordisk.com/science/partnering
Protein Delivery Devices
Morten Bæk JensenInnovation Sourcing Director, e-mail: [email protected]
Our partneringfocus
New device and primary packaging concepts and technologies
• Injection of soluble protein formulations
• Reconstitution and infusion of lyophilised protein formulations
Device Sourcing
